Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06422156 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Nim-PC-28
Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of SBRT combined with Nimotuzumab and mono-chemotherapy in the treatment of locally advanced pancreatic cancer (LAPC).

NCT ID: NCT06329947 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Start date: May 22, 2024
Phase: Phase 2
Study type: Interventional

To preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mFOLFOX6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer

NCT ID: NCT05657418 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Start date: December 30, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.

NCT ID: NCT05298020 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, exploratory study to evaluate efficacy and safety of envafolimab combined with endostar and nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer.

NCT ID: NCT05100329 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Start date: November 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mitoxantrone hydrochloride liposome injection in patients with advanced pancreatic cancer.

NCT ID: NCT04707118 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Start date: February 23, 2021
Phase: Phase 1
Study type: Interventional

In view of the existence of malignant ascites in patients with advanced pancreatic cancer, we put forward the heat abdominal cavity perfusion chemotherapy combined albumin paclitaxel and gemcitabine compared with albumin paclitaxel and gemcitabine prospective clinical study, to assess abdominal albumin hot perfusion chemotherapy combined control of ascites and taxol in improving patients' quality of life, survival, exploring the feasibility of celiac hot perfusion chemotherapy combined albumin paclitaxel and side effects.

NCT ID: NCT04217096 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.

NCT ID: NCT03662035 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

ASPC
Start date: September 15, 2018
Phase: Phase 2
Study type: Interventional

The aim of this study was to determine the efficacy and safety of apatinib combined with S-1 on advanced pancreatic cancer patients after failure of first-line chemotherapy.